The Surgeon Defending Statins, GLP-1s, and Ancel Keys | Dr Terry Simpson

What It Covers

Bariatric surgeon Terry Simpson discusses his personal use of tirzepatide (Zepbound), the 20-year research history behind GLP-1 medications, cardiovascular risk reduction through statins and ApoB management, and the Mediterranean diet's evidence base. Simpson also addresses misinformation around Ancel Keys, seed oils, statins, and carnivore diets, drawing on his clinical experience and familial hypercholesterolemia diagnosis.

Key Questions Answered

• •GLP-1 Medications vs. Native GLP-1: Native GLP-1 produced by the body lasts roughly two minutes before breaking down, making food-based or probiotic strategies to raise it physiologically insignificant compared to medications like tirzepatide, which has a five-day half-life. This sustained elevation produces hypothalamic effects — reducing food noise, dampening reward responses to alcohol, tobacco, and cocaine — that are biologically impossible to replicate through diet or supplementation alone.
• •Food Noise as an Unequal Biological Variable: Food noise — the persistent mental preoccupation with eating — varies significantly between individuals and is not a willpower deficit. Simpson reports noticing its absence within 12 hours of his first tirzepatide injection, describing the shift as analogous to leaving a noisy city and suddenly noticing silence. People who successfully lose weight through diet alone may simply have lower baseline food noise, making their experience non-generalizable to others.
• •Obesity as a Chronic Disease Requiring Ongoing Treatment: Stopping GLP-1 medications causes weight regain because obesity is a chronic disease, not a resolved condition. Simpson compares discontinuing tirzepatide to stopping antihypertensives — blood pressure rebounds. The World Health Organization classified obesity as a chronic disease in 1994, and the American Medical Association followed in 2003. Framing GLP-1 cessation as failure misunderstands disease biology; ongoing treatment is the medically appropriate model.
• •Familial Hypercholesterolemia and the Limits of Diet: Simpson reduced his LDL from 190 to 180 mg/dL through strict Mediterranean diet adherence — a change he equates to cutting from three packs of cigarettes daily to two and a half. Meaningful cardiovascular risk reduction required adding rosuvastatin (Crestor) and ezetimibe, bringing his LDL into the 40s and ApoB to 45–46. For people with genetic hypercholesterolemia, dietary intervention alone is insufficient to reach therapeutically relevant lipid targets.
• •Ancel Keys Was Not a Low-Fat Advocate: Keys' Seven Countries Study is routinely mischaracterized online. He never claimed dietary cholesterol was the primary driver of heart disease, and the Mediterranean diet he studied derives roughly 30% of calories from fat, predominantly olive oil. The Lyon Diet Heart Study, placing post-heart-attack patients on a Mediterranean diet, showed 75% fewer second heart attacks at one year versus a standard French diet — a result significant enough to halt the trial early.
• •Compounded GLP-1 Medications Carry Disproportionate Risk: Approximately 80% of emergency room complications from GLP-1 medications originate from compounded versions, not FDA-approved products. Compounded drugs lack mandatory dose accuracy testing (FDA-approved drugs must be within 10% of stated dose), ingredient disclosure requirements, and sterile reconstitution oversight. Many compounded peptides imported for "research purposes only" meet animal-grade quality standards, not human pharmaceutical standards, making them a materially different and riskier product.
• •Mediterranean Diet Adherence Predicts Long-Term Bariatric Surgery Outcomes: In a study of 186 post-bariatric surgery patients using a validated nine-point Mediterranean diet scoring scale, patients scoring five to nine maintained weight loss at five years. Patients scoring zero to three typically regained weight or failed to reach expected loss targets. Patients scoring four showed scattered outcomes in either direction. This data suggests diet quality — not just caloric restriction — is a reliable predictor of sustained surgical weight loss outcomes.